Our initial experiments concerning the impact of MEK inhibitors on the T cell response were less encouraging, in that these in vitro assays showed strong suppression of T cell activation already at drug concentrations lower than those effective against tumor cells. This evidence concerns the gene MAP2K7 and neoplasm.